Abingdon Health PLC (AIM:ABDX) picked up 10% on an £800,000 grant as part of a €5 million project to find a new early-stage diagnostic test for the malaria parasite.
AIM-listed Abingdon will be part of a group including Institut Pasteur, the Armauer Hansen Research Institute in Ethiopia, FIND, London School of Hygiene & Tropical Medicine (LSHTM) and Walter and Eliza Hall Institute of Medical Research (WEHI) that will work on the two-year project.
Abindgon will lead the lead development of a point-of-care (POC) rapid diagnostic test (RDT) for Plasmodium vivax (P.vivax) infection to support in-field testing and treatment to facilitate malaria control strategy.
Once the RDT has successfully been developed, Abingdon Health will transfer the product to diaTROPIX, a Senegalese manufacturing organisation based at Institut Pasteur Dakar.
Chris Yates, Abingdon Health chief executive, commented: " Working with the Institut Pasteur, FIND, LSHTM, and WEHI gives us a great opportunity to produce rapid tests to aid the management of malaria."
Shares rose 0.75p to 8.5p.